Month: October 2026

Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.

Guggenheim Securities 3rd Annual Healthcare Innovation Conference
November 9 – 11, 2026 in Boston, MA
Fireside chat on November 10 at 9:30 AM EST
InflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and its replay is available here.

Jefferies Global Healthcare Conference
November 16 – 19, 2026 in London, UK
One-on-one investor meetings
Jefferies will organize one-on-one investor meetings with InflaRx on November 16^th and 17^th.

Third quarter 2026 earnings and operating results

The Company will report its third quarter 2026 financial and operating results on November 3, 2026, before the market opens, via a Form 6-K with the U.S. Securities and Exchange Commission (SEC). An update regarding quarterly results will be included during the Capital Markets Day.

Capital Markets Day

As previously announced, InflaRx will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. Featuring leading experts in the fields of ANCA-associated vasculitis (AAV) and complement inhibition, the event will provide an overview of the evolving treatment landscape and unmet need in AAV, and how izicopan’s differentiated chemistry, metabolic properties, and potential safety advantages could improve upon the existing standard of care in AAV.

The event will also provide updated thinking on InflaRx’s development strategy in AAV, including an overview of the anticipated clinical program. The event will feature presentations from members of InflaRx’s management team and invited external experts, followed by a question-and-answer session. To participate in the virtual event, participants are requested to pre-register here to receive an invite link and dial-in details to access the event.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx and the group have offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

SalesCloser’s AI sales agents now answer leads on WhatsApp in seconds, at any hour, with the business’ own services, pricing and hours

Extends the Company’s multi-channel platform

Vancouver, BC, Oct. 27, 2026 (GLOBE NEWSWIRE) — SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, today announced the launch of WhatsApp as a new native channel for its AI sales agents. When a lead messages a business through WhatsApp, the SalesCloser agent replies in seconds, day or night, with the business’ own services, pricing and open hours, and hands off to a person whenever the lead asks to speak with one. WhatsApp is already live in SalesCloser, activated at each customer’s request.

The new channel extends the ways SalesCloser agents already engage leads, alongside voice, video and digital channels. WhatsApp conversations land in a new Chats tab inside the SalesCloser dashboard, which works like a familiar chat application: every WhatsApp thread appears in one place, with conversations that need a human pinned to the top.

When a lead asks to speak with a real person, the AI agent does not improvise. It tells the lead the team has been notified, pauses itself, and emails the business immediately with the reason and a direct link to the conversation. Replies sent from the dashboard reach the lead on WhatsApp. While a person is in the conversation, the agent stays quiet; one click hands the conversation back, and the agent resumes where it left off. If no one replies in time, the agent takes the conversation back and lets the lead know the team will follow up.

The launch extends SalesCloser’s multi-channel story. The platform already runs conversations across voice, video and digital channels, and WhatsApp builds on the same agent and knowledge base.

WhatsApp is the default business messaging channel across much of the world. More than three billion people use WhatsApp across over 180 countries, including more than 100 million monthly users in the United States, and it was the most used social network in Latin America as of the second quarter of 2025. For SalesCloser, WhatsApp support removes an adoption blocker in markets where leads expect to be reached on WhatsApp and adds a lead channel for customers in North America.

“Leads are on WhatsApp, so our agents needed to be there too,” said Ali Tajskandar, Chief Executive Officer of SalesCloser. “The agent that already answers voice and website conversations now answers WhatsApp, with the business’s own services, pricing and hours, and with human handoff designed into the flow. When a lead asks for a person, the team is notified instantly and can step in, and the agent picks up exactly where it left off. For our customers, that means one agent, one knowledge base and the same human-in-the-loop controls, on the channel their leads already use.”

See WhatsApp in action: watch the Company’s demo video of a SalesCloser AI sales agent answering a lead: https://www.youtube.com/watch?v=H5KC5M3G3ls

About SalesCloser
SalesCloser.ai is a Vancouver-based AI software company focused on automating and scaling revenue generation through conversational AI. The Company’s platform enables businesses to deploy AI-powered virtual sales agents that engage prospects and customers across the sales lifecycle. SalesCloser’s agents conduct real-time, personalized interactions across voice, video, and digital channels, including lead qualification, product demonstrations, follow-ups, and meeting scheduling. By augmenting core sales functions, the platform is designed to help organizations increase capacity, accelerate pipeline velocity, and improve conversion rates without a corresponding increase in headcount. The platform integrates with existing CRM and business systems, supports multilingual deployment, and is intended to deliver consistent customer interactions across industries. SalesCloser operates under a subscription-based SaaS model, generating recurring revenue, while continuing to develop its AI capabilities. The Company’s technology is supported by a growing portfolio of patents and patent applications focused on improving the performance of AI-driven conversational workflows. SalesCloser.ai is listed on the TSX Venture Exchange under the ticker “SCAI”, on the OTCQB Venture Market under the ticker “SCTLF”, and on the Frankfurt Stock Exchange under the ticker “MJ5”. For more information, visit the SalesCloser investor site at: https://investors.salescloser.ai

Corporate Contact
Adrian Lim, CFO
Email: investors@salescloser.ai
Phone: 778-655-4329

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
SCAI@arxhq.com

Forward-Looking Statements
Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about: the launch, features, capabilities, performance, and anticipated benefits of WhatsApp as a new channel and of the Chats tab and the handoff between AI agents and human teams; the expected ability of the Company’s AI sales agents to engage leads on WhatsApp and to hand conversations between agents and human teams; customer adoption, engagement, and retention; the expectation that WhatsApp will lower a barrier to adoption for businesses in markets where it is the primary business messaging channel; the Company’s technology roadmap and the expected benefits of its patent applications, including the application covering hybrid session management across text, voice and avatar channels; future growth and increased use of products incorporating artificial intelligence; the Company’s ability to scale operations and expand across diverse industry verticals and geographies; revenue growth and recurring SaaS revenue; technology development initiatives; commercial expansion and go-to-market strategies; future profitability; business opportunities, objectives, and prospects; and future events and performance. Sentences containing words such as “expect”, “anticipate”, “plan”, “continue”, “estimate”, “intend”, “may”, “will”, “project”, “predict”, “potential”, “is designed to”, “strategy”, “should”, “believe”, “contemplate” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on material assumptions, including that the WhatsApp channel and related features will perform as designed, continued demand for conversational AI, the continued availability of the WhatsApp Business platform and its terms, the Company’s ability to attract customers and platform partners, competition within the AI space, and general economic conditions. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and based on current market trends and analysis of management, such statements are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to: risks that the WhatsApp channel, the Chats tab, or the human handoff functionality do not perform as expected, experience technical difficulties, or fail to achieve commercial adoption; risks associated with the Company’s reliance on the WhatsApp Business platform, including changes to its terms, pricing, or availability; risks associated with delays in the development or rollout of new features; changes to SalesCloser’s revenue and profitability; changes to customer preferences and demand for conversational AI; competition from larger technology companies or other conversational AI providers; reliance on third-party service providers, cloud infrastructure, and software platforms; risks that third parties develop competing technology or assert intellectual property infringement; data security, privacy, and regulatory compliance risks; economic uncertainty, inflation, interest rate fluctuations, and recessionary risks; and the additional risk factors discussed in the continuous disclosure materials of the Company available under its profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are made as of the date hereof and the Company disclaims any obligation to update or revise them, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

– ARCALYST^® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –
– ARCALYST 2026 expected net product revenue increased to $1.045 – $1.050 billion –
– KPL-387 pivotal Phase 3 data expected in 2H 2027 –
– Conference call and webcast scheduled for 8:30 am ET today –

LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution.

“Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third quarter, strong commercial execution led to gains in patient and physician adoption, resulting in revenue of $286.0 million and positioning ARCALYST to achieve blockbuster status this year,” said Sanj K. Patel, Chairman & Chief Executive Officer of Kiniksa. “Our robust financial position supports continued investment in value creation through ARCALYST, KPL-387, and KPL-1161. We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million. Additionally, we continue to enroll and dose patients in PASTORALE, the pivotal Phase 3 trial of KPL-387 evaluating once monthly subcutaneous dosing. We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe. We remain on track to initiate a Phase 1 trial of KPL-1161 by the end of this year.”

Portfolio Execution
ARCALYST (IL-1α and IL-1β cytokine trap)

• ARCALYST net product revenue was $286.0 million for the third quarter of 2026.
• As of the end of the third quarter of 2026, approximately 23% of the 14,000 annual multiple-recurrence patients were actively on ARCALYST treatment.
• Since launch, more than 5,450 prescribers have written ARCALYST prescriptions for recurrent pericarditis.
• As of the end of the third quarter of 2026, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 3 years, in line with the median duration of disease.

KPL-387 (monoclonal antibody IL-1 receptor antagonist)

• Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027.
• Kiniksa is also conducting a supplemental Phase 2 Transition to KPL-387 Monotherapy Dosing and Administration Study evaluating the transition of patients from standard therapies to KPL-387 monotherapy.

KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist)

• Kiniksa expects to initiate a Phase 1 first-in-human clinical trial of KPL-1161 with a target profile of quarterly subcutaneous (SC) dosing by the end of 2026.

Financial Results

• Total revenue for the third quarter of 2026 was $286.0 million, compared to $180.9 million for the third quarter of 2025.
• Total operating expenses for the third quarter of 2026 were $231.7 million, compared to $156.8 million for the third quarter of 2025, and comprised the following:
  • Cost of Goods Sold (COGS) expenses of $27.8 million, compared to $20.3 million for the third quarter of 2025. The increase in COGS expenses was primarily due to costs associated with increased sales of ARCALYST.
  • Collaboration expenses of $105.8 million, compared to $63.3 million for the third quarter of 2025. Collaboration expenses are driven primarily by ARCALYST collaboration profitability.
  • Research and Development (R&D) expenses of $32.8 million, compared to $24.2 million for the third quarter of 2025. The increase in R&D expenses was primarily due to increased KPL-387 clinical activity.
  • Selling, General, and Administrative (SG&A) expenses of $65.4 million, compared to $49.1 million for the third quarter of 2025. The increase in SG&A expenses was primarily due to investment associated with the commercialization of ARCALYST.
  • Total operating expenses for the third quarter of 2026 included $13.1 million in non-cash, share-based compensation expense, compared to $10.1 million for the third quarter of 2025.
• Net income for the third quarter of 2026 was $47.3 million, compared to $18.4 million for the third quarter of 2025.
• As of September 30, 2026, Kiniksa had $568.8 million of cash, cash equivalents, and short-term investments and no debt.

Financial Guidance

• Kiniksa expects 2026 ARCALYST net product revenue of between $1.045 billion and $1.050 billion, compared to prior guidance of between $980 million and $995 million.
• Kiniksa expects 2026 R&D expenses of between $160 million and $170 million and 2026 SG&A expenses of between $270 million and $280 million.
• Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.

Conference Call Information

• Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 27, 2026, to discuss third quarter 2026 financial results and recent portfolio execution.
• Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

About ARCALYST
ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST

• ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
• While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret^® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel^® (etanercept), Humira^® (adalimumab), or Remicade^® (infliximab), as this may increase your risk of getting a serious infection.
• Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
• Medicines that affect the immune system may increase the risk of getting cancer.
• Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
• Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
• Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, talk to your doctor and see the Product Information.

About KPL-387
KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines IL-1α and IL-1β. Kiniksa believes KPL-387 could expand the treatment options for recurrent pericarditis patients by potentially enabling dosing with a single monthly SC self-injection in a liquid formulation. In October 2025, the FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis.

About PASTORALE
PASTORALE is a double-blind, placebo controlled, randomized withdrawal (RW) study enrolling up to approximately 85 patients with recurrent pericarditis. In the first period, a single-blind run-in (RI), all participants will receive KPL-387 while conventional oral pericarditis medications are weaned and discontinued. Participants achieving Clinical Response in the RI period will then be randomized in a 1:1 ratio to receive either KPL-387 300 mg SC once-monthly or placebo in an event-driven, double-blind, RW period. The primary efficacy endpoint is time to first-adjudicated pericarditis recurrence during the RW period. Participants in the RW period may be eligible to enter a long-term extension.

About KPL-1161
KPL-1161 is an independently developed, investigational, Fc-modified IgG2 monoclonal antibody that binds IL-1R1, inhibiting the signaling of the cytokines IL-1α and IL-1β, with a target profile of quarterly SC dosing. Kiniksa is currently engaging in preclinical development activities for KPL-1161.

Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST will achieve blockbuster status in 2026 with net product revenue between $1.045 billion and $1.050 billion; our expectation to have data from our pivotal Phase 3 trial of KPL-387 in recurrent pericarditis in the second half of 2027; our expectation to begin commercialization of KPL-387 in 2028 or 2029; our belief that we are on track to initiate a Phase 1 first-in-human clinical trial of KPL-1161 by the end of 2026; the target profiles for our product candidates, including a once-monthly subcutaneous dosing profile for KPL-387 and a once-quarterly subcutaneous dosing profile for KPL-1161; our expectations that 2026 annual R&D expenses will be between $160 million and $170 million and that 2026 annual SG&A expenses will be between $270 million and $280 million; our expectation that our current operating plan will remain cash flow positive on an annual basis; our beliefs about the mechanisms of our assets and potential impact of their approach; statements regarding our belief about the future of our commercial opportunities; and our belief that our portfolio of assets offers the potential for differentiation.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials, including the data from our ongoing clinical trials of KPL-387 in recurrent pericarditis; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; business development activities and their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; and the impact of global economic policy, including any uncertainty in national and international markets.

These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SELECTED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
								Three Months Ended								Nine Months Ended
								September 30,								September 30,
								2026				2025				2026				2025
Revenue:
		Product revenue, net						$	285,970			$	180,855			$	743,836			$	475,437
		License and collaboration revenue							—				—				—				—
				Total revenue					285,970				180,855				743,836				475,437
Operating expenses:
		Cost of goods sold							27,759				20,257				72,127				56,728
		Collaboration expenses							105,828				63,307				269,474				159,515
		Research and development							32,786				24,166				101,160				62,244
		Selling, general and administrative							65,361				49,104				190,378				139,497
				Total operating expenses					231,734				156,834				633,139				417,984
Income from operations									54,236				24,021				110,697				57,453
Other income, net									4,821				3,136				12,186				8,146
Income before income taxes									59,057				27,157				122,883				65,599
Provision for income taxes									(11,712	)			(8,722	)			(27,514	)			(20,793	)
Net income								$	47,345			$	18,435			$	95,369			$	44,806
Net income per share attributable to ordinary shareholders—basic								$	0.61			$	0.25			$	1.23			$	0.61
Net income per share attributable to ordinary shareholders—diluted								$	0.56			$	0.23			$	1.14			$	0.57
Weighted average ordinary shares outstanding—basic									78,192,603				74,714,846				77,435,077				73,605,690
Weighted average ordinary shares outstanding—diluted									84,920,060				80,035,400				83,713,015				78,027,370

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
(Unaudited)
								As of
								September 30,				December 31,
									2026				2025
Cash, cash equivalents, and short-term investments								$	568,758			$	414,074
Working capital									558,244				387,993
Total assets									983,243				763,633
Accumulated deficit									(366,769	)			(462,138	)
Total shareholders’ equity									710,193				567,606

SATO Corporation, Stock Exchange Release 27 October 2026 at 1:30 pm

In 2027, SATO will publish its financial reports according to the following schedule:

12 February 2027	Financial Statements Release for 2026
13 May 2027	Interim Report for 1 January–31 March 2027 (Q1)
14 July 2027	Half-year Report for 1 January–30 June 2027 (H1)
29 October 2027	Interim Report for 1 January–30 September 2027 (Q3)

The Annual Report for 2026 will be published on SATO’s website at www.sato.fi/en during week 6.

The Annual General Meeting of SATO Corporation will be held on Thursday, 18 March 2027, starting at 1:00 pm. The notice of the AGM will be disclosed separately once the Board of Directors has convened the meeting.

A shareholder is entitled to demand a matter for discussion at the AGM, if such matter falls under the competence of a General Meeting according to the Finnish Companies Act. A written request shall be provided to SATO Corporations’s Board of Directors either by e-mail to yhtiokokous@sato.fi or by mail addressed to SATO Corporation / Annual General Meeting, Panuntie 4, P.O. Box 401, 00601 Helsinki, Finland by 22 January 2027.

For more information, please contact:
Markku Honkasalo, CFO, SATO Corporation, phone +358 201 34 4226, markku.honkasalo@sato.fi

Distribution: Euronext Dublin, main media, www.sato.fi/en

SATO Corporation is one of Finland’s largest rental housing providers owning around 27,500 rental homes in the Helsinki Metropolitan Area, Tampere and Turku. SATO aims to provide excellent customer experience and a comprehensive range of urban rental housing alternatives with good access to public transport and services. SATO invests profitably, sustainably and with a long-term view. We increase the value of our assets through investments, divestments and repairs. In 2025 SATO celebrated its 85^th anniversary. www.sato.fi/en